Ascendis Pharma Retained Earnings (Accumulated Deficit) 2015-2024 | ASND

Ascendis Pharma retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $-2.664B, a 18.66% increase year-over-year.

  • Ascendis Pharma retained earnings (accumulated deficit) for 2023 were $-2.465B, a 25.73% increase from 2022.
  • Ascendis Pharma retained earnings (accumulated deficit) for 2022 were $-1.96B, a 17.19% increase from 2021.
  • Ascendis Pharma retained earnings (accumulated deficit) for 2021 were $-1.673B, a 42.13% increase from 2020.

Ascendis Pharma Retained Earnings (Accumulated Deficit) 2015-2024 | ASND

  • Ascendis Pharma retained earnings (accumulated deficit) for 2023 were $-2.465B, a 25.73% increase from 2022.
  • Ascendis Pharma retained earnings (accumulated deficit) for 2022 were $-1.96B, a 17.19% increase from 2021.
  • Ascendis Pharma retained earnings (accumulated deficit) for 2021 were $-1.673B, a 42.13% increase from 2020.